Continuous Glucose Monitoring Devices (CGMs)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	Receiver: One time Sensors and transmitters: 1 year

Continuous Glucose Monitoring Devices (CGMs) – including sensor, transmitter, receiver	Comments
Dexcom Product Line	Preferred^
Freestyle Libre Product Line Eversense Product Line Medtronic Product Lines for the following products: • Enlite sensors • Guardian (monitors, receivers, sensors, transmitters) • Minimed Guardian sensor • Sof-sensor ^Step Therapy Does not apply in California	Non-Preferred^

Product/Product Line	Quantity Limit
Dexcom G5 Receiver*	1 receiver per year (based on manufacturer warranty)
Dexcom G5 Transmitter	1 transmitter per 90 days
Dexcom G5 Sensor	4 sensors per 28 days
Dexcom G6 Receiver*	1 receiver per year (based on manufacturer warranty)
Dexcom G6 Transmitter	1 transmitter per 90 days
Dexcom G6 Sensor	3 sensors per 30 days
Dexcom G7 Receiver*	1 receiver per year (based on manufacturer warranty)
Dexcom G7 Sensor	3 sensors per 30 days

Freestyle Libre reader*	1 reader per year (based on manufacturer warranty)
Freestyle Libre 14 day Reader*	1 reader per year (based on manufacturer warranty)
Freestyle Libre 14 day Sensor	2 sensors per 28 days
Freestyle Libre 2 Reader*	1 reader per year
Freestyle Libre 2 Sensor	2 sensors per 28 days
Freestyle Libre 3 Reader*	1 reader per year
Freestyle Libre 3 Sensor	2 sensors per 28 days
Guardian Connect Transmitter*	2 transmitters per year
Guardian Sensor (3)	5 sensors per 30 days
Guardian 4 Transmitter*	1 transmitter per year
Guardian Sensor (4)	5 sensors per 30 days
Eversense Smart Transmitter*	1 transmitter per year
Eversense 365 Smart Transmitter*	1 transmitter per year
Eversense 365 Sensor	1 sensor per year

APPROVAL CRITERIA

Step Therapy for non-preferred agents

All states except for CA - Requests for non-preferred continuous glucose monitoring (CGM) devices and CGM supplies (receiver, transmitter, sensor) must meet the following criteria:

I. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response or intolerance to the preferred continuous glucose monitor (Dexcom Product Line); **OR**
II. Individual utilized an insulin pump that is only compatible with a non-preferred continuous glucose monitor.

CA – Step Therapy does not apply

Prior Authorization for all agents

Initial requests for p*ersonal long-term use* of non-implanted and implanted continuous glucose monitoring device (CGM) and CGM supplies may be approved if the following criteria are met:

I. Individual has been diagnosed with diabetes mellitus (any type); **AND**
II. Insulin injections are required multiple times daily or an insulin pump is used for maintenance of blood sugar control; **AND**,
III. Individual or caregiver(s) demonstrates the following:
    A. An understanding of the technology, including but not limited to the use of the device to recognize alerts and alarms; **AND**
    B. Motivation to use the device correctly and consistently; **AND**
    C. Continued participation in a comprehensive diabetes treatment plan; **AND**
IV. Any of the following are present despite ongoing management using self-monitoring and insulin administration regimens to optimize care:
    A. Inadequate glycemic control, demonstrated by HbA1c measurements above target; **OR**
    B. Persistent fasting hyperglycemia; **OR**
    C. Recurring episodes of hypoglycemia (blood glucose <50 mL/dL); **OR**
    D. Hypoglycemia unawareness that puts the individual or others at risk; **OR**
    E. In children and adolescents with type 1 diabetes who have achieved HbA1c levels below 7%, when treatment is intended to maintain target HbA1c levels and limit the risk of hypoglycemia;

AND

V. If requesting an implantable CGM (Eversense), individual must be 18 years of age or older.

Continuation requests for non-implanted and implanted continuous glucose monitoring devices (CGM) and CGM supplies may be approved if the following criteria are met:

I. Individual met the initiation criteria at the time of the first request for the CGM device; **AND**

The CGM device has resulted in desired clinical benefit (including but not limited to HbA1c control or fewer episodes of symptomatic hypoglycemia or hyperglycemia).

***Quantity Override:**

The *replacement* of non-implanted continuous interstitial glucose monitoring devices may be approved when the following criteria have been met:

A. The device is out of warranty; **AND**
B. The device is malfunctioning; **AND**
C. The device cannot be refurbished.

The *replacement* of implanted continuous interstitial glucose monitoring devices may be approved when the following criteria have been met:

I. Individual met the initiation criteria at the time of the first request for the CGM device.

Use of personal non-implanted and implanted continuous glucose monitoring devices (CGM) and CGM supplies may not be approved when the above criteria are not met and for all other indications.

Key References:

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. http://dailymed.nlm.nih.gov/dailymed/about.cfm.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2023; Updated periodically.
4. Tamborlane WV, Beck RW, Bode BW, et al.; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008; 359(14):1464-1476.
5. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Effectiveness of continuous glucose monitoring in a clinical care environment. Diabetes Care. 2010; 33(1):17-22.
6. Battelino T, Phillip M, Bratina N, et al. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care. 2011; 34(4):795-800.
7. Heinemann L, Freckmann G, Ehrmann D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet. 2018; 391(10128):1367-1377.
8. ElSayed NA, Aleppo G, Aroda VR, et al. 7. Diabetes Technology: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S111-S127. doi:10.2337/dc23-S007.
9. Shatlin S, Phillip M. Hypoglycemia in type 1 diabetes: A still unresolved problem in the era of insulin analogs and pump therapy. Diabetes Care; 2008 Feb; 31(supplement 2): S121-S124. Available from: https://care.diabetesjournals.org/content/31/Supplement_2/S121.
10. Diabetes Control and Complications Trial Research Group (DCCT). Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J of Pediatr. 1994; 125(2):177-188.
11. Feig DS, Donovan LE, Corcoy R, et.al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet. 2017 Nov 25;390(10110):2347-2359. doi: 10.1016/S0140-6736(17)32400-5. Epub 2017 Sep 15. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5713979/.
12. Fonseca VA, Grunberger G, Anhalt H, et.al. Continuous glucose monitoring: A consensus conference of the American Association of Clinical Endocrinologists and American College of Endocrinology. Endocrine Practice. 2016; 22(8):1008-1021. Available from: https://journals.aace.com/doi/pdf/10.4158/EP161392.CS.
13. Heller SR. International Hypoglycaemia Study Group (IHSG): Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2017;40:155–157. Available from https://care.diabetesjournals.org/content/40/1/155.
14. DeSalvo DJ, Miller KM, Hermann JM, et al. Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: International comparison from the T1D Exchange and DPV Initiative. Pediatr Diabetes. 2018;19:1271–1275. 10.1111/pedi.12711.
15. Guardian Connect User Guide. Available from: https://www.medtronicdiabetes.com/sites/default/files/library/download-library/user-guides/GuardianT%20Connect%20CGM%20System%20User%20Guide.PDF. Accessed December 9, 2022.
16. Dexcom G6 User Guide. Available from: https://s3-us-west-2.amazonaws.com/dexcompdf/G6-CGM-Users-Guide.pdf. Accessed December 9, 2022.
17. Dexcom G5 User Guide. Available from: https://s3-us-west-2.amazonaws.com/dexcompdf/G5-Mobile-Getting-Started-Guide-Touchscreen-Receiver.pdf. Accessed December 9, 2022.
18. Freestyle Libre User Guide: Available from: https://freestyleserver.com/Payloads/IFU/2018/ART38553-101_rev-A.pdf. Accessed December 9, 2022.
19. Freestyle Libre 14 day User Guide: Available from: https://freestyleserver.com/Payloads/IFU/2018/ART39764-001_rev-A-Web.pdf. Accessed December 9, 2022.
20. Freestyle Libre 3 User Guide: Available from: https://freestyleserver.com/Payloads/IFU/2022/ART44255-001_rev-A-Web.pdf. Accessed December 9, 2022.

Federal and state laws or requirements, contract language, and Plan utilization management programs or polices may take precedence over the application of this clinical criteria.